Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 8;10:596087. doi: 10.3389/fonc.2020.596087

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zhang, Zheng, Yang, Li, Wang, Yao, Deng, Li, Wei, Wu, Zhu, Li and Dai

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

KM survival subgroup analysis of all patients with BC according to the GRG‐related gene signature stratified by clinical characteristics. (A) Age <60 y, Age >=60 y. (B) Early stage (stages I–II), Late stage (stages III–IV). C, T1-2, T3–4. (D) Lymph node-negative patients, Lymph node-positive patients. (E) Patients without distal metastasis, patients with distal metastasis. (F) ER-negative patients, ER-positive patients. (G) PR-negative patients, PR-positive patients. (H) HER2-negative patients, HER2-positive patients. (I) No adjuvant therapy, adjuvant therapy. GRGs, glycolysis-related genes; BC, breast cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2.